VRPX Virpax Pharmaceuticals
- 2.8000
- -0.3000-9.68%
Virpax Pharmaceuticals News
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersBio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. The company's market cap stands at $3.4 million. Biora Therapeutics (NASDAQ:BIOR) share
Virpax Pharmaceuticals to Offer Stock and Warrants
Virpax Pharmaceuticals to Offer Stock and Warrants
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersLongeveron (NASDAQ:LGVN) shares moved upwards by 75.0% to $3.85 during Monday's pre-market session. The market value of their outstanding shares is at $9.6 million. PetVivo Hldgs (NASDAQ:PETV)
Express News | On April 2, Virpax Pharmaceuticals Inc Got Letter From Nasdaq Stating That Company Was Not In Compliance With Nasdaq Listing Rule
Virpax Pharmaceuticals' Settlement Strain: Risk of Stalled Development and Hindered Growth
Virpax Pharmaceuticals GAAP EPS of -$12.97 Misses by $4.77
Express News | Virpax Pharma Reported FY23 EPS Loss of $(12.97) Vs $(9.20) Est, Cash Balance of $9.1M
Press Release: Virpax Pharmaceuticals Reports 2023 Year-End Results
Virpax Pharmaceuticals Reports 2023 Year-End Results BERWYN, Pa.--(BUSINESS WIRE)--March 26, 2024-- Virpax(R) Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing
Virpax Pharmaceuticals Strong Start Tp 2024 >VRPX
Virpax Pharmaceuticals Strong Start Tp 2024 >VRPX
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersEtao International Co (NASDAQ:ETAO) stock rose 249.4% to $0.5 during Tuesday's after-market session. The company's market cap stands at $51.1 million. Taysha Gene Therapies (NASDAQ:TSHA) shares
Express News | Virpax Pharmaceuticals SaidOn March 15, Got Letter From Nasdaq That Co Has Regained Compliance With Listing Rule 5550(A)(2)
Express News | Scilex Pharmaceuticals Inc., Entered Definitive Mutual Release And Settlement Agreement With Virpax Pharmaceuticals, Inc. Relating To Previously Announced Term Sheet With Virpax In Respect Of Such Release And Settlement
Virpax Pharmaceuticals To Carry Out 1-for-10 Reverse Stock Split On March 1st, 2024
February 28th - $Virpax Pharmaceuticals(VRPX.US)$ is about to implement a 1-for-10 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from March 1st, 2024.$Virpax P
Express News | Virpax Pharmaceuticals Shares Are Trading Lower After the Company Announced a Proposed Settlement of Litigation With Sorrento Therapeutics and Scilex Pharmaceuticals. Also, the Company Announced a 1-for-10 Reverse Stock Split
Express News | Virpax Pharmaceuticals Announces 1-For-10 Reverse Stock Split to Regain Compliance With Nasdaq's Minimum Bid Price, Effective March 1, 2024
Virpax Pharmaceuticals Announces Reverse Stock Split To Regain Compliance With Nasdaq's Minimum Bid Price >VRPX
Virpax Pharmaceuticals Announces Reverse Stock Split To Regain Compliance With Nasdaq's Minimum Bid Price >VRPX
Virpax Pharmaceuticals Will Effect a 1-For-10 Reverse Stk Split of Its Common Stk, Effective at 12:01 A.m. ET on March 1 >VRPX
Virpax Pharmaceuticals Will Effect a 1-For-10 Reverse Stk Split of Its Common Stk, Effective at 12:01 A.m. ET on March 1 >VRPX
Express News | Scilex Pharmaceuticals Inc. Enters Into Term Sheet With Virpax Pharmaceuticals, Inc. Regarding A Mutual Release And Settlement Agreement
Analysts Offer Insights on Healthcare Companies: Virpax Pharmaceuticals (VRPX) and I-MAB (IMAB)
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study With the U.S. Army Institute of Surgical Research
Virpax Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS)
Analysis
Price Target
No Data
